Dr. Linda Van Le
Claim this profileUNC Lineberger Comprehensive Cancer Center
Area of expertise
Ovarian Cancer
Linda Van Le has run 7 trials for Ovarian Cancer. Some of their research focus areas include:
Fallopian Tube Cancer
Linda Van Le has run 5 trials for Fallopian Tube Cancer. Some of their research focus areas include:
Affiliated Hospitals
UNC Lineberger Comprehensive Cancer Center
University Of North Carolina At Chapel Hill
Clinical Trials Linda Van Le is currently running
CAR-T Cells
for Ovarian Cancer
The purpose of this study is to test the safety and tolerability of using a new treatment called autologous T lymphocyte chimeric antigen receptor cells against the B7-H3 antigen (iC9-CAR.B7-H3 T cells) in patients with ovarian cancer that came back after receiving standard therapy for this cancer. The iC9.CAR.B7-H3 treatment is experimental and has not been approved by the Food and Drug Administration. The study team wants to know how much (dose) of the iC9-CAR.B7-H3 T cells are safe to use in patients without causing too many side effects and what is the maximum dose could be tolerated. There are two parts to this study. In part 1, approximately blood will be collected from subjects to prepare the iC9.CAR.B7-H3 T cells. The study team will collect disease-fighting T cells from the blood and modify them to prepare the iC9.CAR.B7-H3 T cells. In part 2, the iC9.CAR.B7-H3 T cells will be given to eligible subjects by infusion three days after completion of lymphodepletion chemotherapy.
Recruiting
1 award
Phase 1
Herceptin Hylecta or Phesgo + Chemotherapy
for Uterine Cancer
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial cancer. Trastuzumab and pertuzumab are monoclonal antibodies and forms of targeted therapy that attach to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When trastuzumab or pertuzumab attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Hyaluronidase is an endoglycosidase. It helps to keep pertuzumab and trastuzumab in the body longer, so that these medications will have a greater effect. Hyaluronidase also allows trastuzumab and trastuzumab/pertuzumab to be given by injection under the skin and shortens their administration time compared to trastuzumab or pertuzumab alone. Paclitaxel is a taxane and in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Giving Herceptin Hylecta or Phesgo in combination with paclitaxel and carboplatin may shrink the tumor and prevent the cancer from coming back in patients with HER2 positive endometrial cancer.
Recruiting
2 awards
Phase 3
More about Linda Van Le
Clinical Trial Related
2 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Linda Van Le has experience with
- Paclitaxel
- Carboplatin
- Topotecan
- External Beam Radiation Therapy
- Pembrolizumab
- Olaparib
Breakdown of trials Linda Van Le has run
Ovarian Cancer
Fallopian Tube Cancer
Endometrial Adenocarcinoma
Uterine Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Linda Van Le specialize in?
Linda Van Le focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved Stage II patients, or patients who are Stage III.
Is Linda Van Le currently recruiting for clinical trials?
Yes, Linda Van Le is currently recruiting for 2 clinical trials in Chapel Hill North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Linda Van Le has studied deeply?
Yes, Linda Van Le has studied treatments such as Paclitaxel, Carboplatin, Topotecan.
What is the best way to schedule an appointment with Linda Van Le?
Apply for one of the trials that Linda Van Le is conducting.
What is the office address of Linda Van Le?
The office of Linda Van Le is located at: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 United States. This is the address for their practice at the UNC Lineberger Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.